Abstract:Osteogenesis imperfecta (OI), an inherited connective tissue disorder of remarkable clinical variability, is caused by a quantitative or qualitative defect in collagen synthesis and is characterised by bone fragility. The number of fractures and deformities, and the age at which they begin greatly influence the prognosis and the achievement of walking and autonomy. A multidisciplinary team approach is essential for diagnosis, for communication with patient and parents, and to tailor treatment needs to the severity of the disease and the age of the patient. Three types of treatment are available: nonsurgical management (physical therapy, rehabilitation, bracing and splinting), surgery (intramedullary rod positioning, spinal and basilar impression surgery), and drugs to increase the strength of bone and decrease the number of fractures. An aggressive rehabilitative approach is indicated to optimise functional ability and walking capacity; appropriately timed surgery to insert intramedullary rods provides improved function of extremities. Despite a high rate of complications, intramedullary telescopic roding has proven to be the most successful method for preventing and correcting fractures and deformities of long bones, improving walking capability and leading to successful rehabilitation of even severely affected patients. Surgery may be required in patients with progressive spinal deformity and in those with symptomatic basilar impression. Hearing function, dentinogenesis imperfecta, cardiac and respiratory function, and neurological changes must be monitored. The causal defect of the disease cannot be corrected with medical treatment and, currently, only symptomatic therapy is available. In recent years growth hormone (GH) and bisphosphonate agents have been used in OI therapy. GH is beneficial in patients with moderate forms of OI, showing a positive effect on bone turnover, bone mineral density and height velocity rate. Bisphosphonates have proved beneficial in children with severe OI, increasing bone mineral density and reducing the fracture rate and pain with no adverse effects reported. These data require confirmation in double-blind controlled studies; however, bisphosphonates have markedly improved morbidity in patients with OI. Future developments in genetic therapy may be directed towards either replacing cells carrying the mutant gene with normal cells or silencing the mutant allele using antisense suppression therapy, thus transforming a biochemically severe form of OI into a mild form.

Bone modeling alteration in premature infants.

Biomarkers and Biochemical Indicators to Evaluate Bone Metabolism in Preterm Neonates

High bone mass phenotype in a cohort of patients with Osteogenesis Imperfecta caused due to BMP1 and C-propeptide cleavage variants in COL1A1

[Bone Turnover and Early Parenteral Calcium Supply in Preterm Infants].

Clinical-laboratory findings of bone metabolism in healthy premature and full-term neonates: preliminary results.

Bone modeling, remodeling, and skeletal health in children and adolescents: mineral accrual, assessment and treatment

Bone Quality and Mineralization and Effects of Treatment in Osteogenesis Imperfecta

Skeletal consequences of preterm birth in pigs as a model for preterm infants.

Prediction of bone metabolism disorders in premature babies

Current concepts in osteogenesis imperfecta: Bone structure, biomechanics and medical management

Altered type I collagen networking in osteoporotic human femoral head revealed by histomorphometric and Fourier transform infrared imaging correlated analyses

Bone fragility and osteoporosis in children and young adults

Metabolic bone disease of prematurity: causes, recognition, prevention, treatment and long-term consequences

Metabolic Bone Disease in Premature Neonates: An Unmet Challenge

Modulation of biomineralization morphology by phosphorylated collagen peptides: insights into osteogenesis imperfecta pathophysiology

The Clinical and Biochemical Predictors of Bone Mass in Preterm Infants

Osteogenesis imperfecta: practical treatment guidelines

Immature porcine cortical bone mechanical properties and composition change with maturation and displacement rate

Management of Osteogenesis Imperfecta

Pleiotropic effects of a recessive C mutation occurring in a mouse model of severe osteogenesis imperfecta

RNA-based bone histomorphometry: method and its application to explaining postpubertal bone gain in a G610C mouse model of osteogenesis imperfecta